18 May,2024 02:30 PM IST | New Delhi | IANS
Image for representational purposes only. Photo Courtesy: iStock
A coloured band (usually white or red) along the length of the nail may indicate the risk of developing cancerous tumours of the skin, eyes, and kidneys, finds a study.
Scientists at the US National Institutes of Health (NIH) discovered the presence of a benign nail abnormality known as an onychopapilloma. Besides the coloured band, it also comes with thickening of the nail underlying the colour change, and thickening at the end of the nail.
This may lead to the diagnosis of a rare inherited disorder, known as BAP1 tumour predisposition syndrome, that increases the risk of developing cancerous tumours, they noted.
Mutations in the BAP1 gene drive the syndrome, "which normally acts as a tumour suppressor, among other functions," revealed the findings published in JAMA Dermatology journal.
Read Also:
Can your nail colour raise risk of cancer? Mumbai experts weigh in on new study
ALSO READ
Mobile phone use can worsen heart disease in smokers, diabetics: Study
No link between sports concussions and cognitive problems: Study
'Cortisol face': Medical and fitness experts dissect the new social media trend
After Sweden restricts screen time for kids, Indian experts express their views
India ranks 38th globally in suicide deaths: Report
The condition typically only affects one nail. However, in the study of 47 individuals with BAP1 syndrome from 35 families, about 88 per cent presented onychopapilloma tumours in multiple nails.
"This finding is rarely seen in the general population, and we believe the presence of nail changes that suggest onychopapillomas on multiple nails should prompt consideration of a diagnosis of BAP1 tumour predisposition syndrome," said Edward Cowen, head of Dermatology Consultation Services at NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
The team suggested that nail screening may be particularly valuable in a patient with a personal or family history of melanoma or other potential BAP1-associated malignancy.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.